News | Radiation Therapy | October 09, 2018

Surgery, Radiation Therapy Equally Effective in Treating Oropharyngeal Cancer

Research results suggest quality-of-life factors should inform treatment decisions

Surgery, Radiation Therapy Equally Effective in Treating Oropharyngeal Cancer

October 9, 2018 — A new study by researchers at UT Southwestern Medical Center found no major long-term differences in the effectiveness of radiation therapy versus surgery in treating an increasingly diagnosed head and neck cancer. Given these results, investigators suggest quality-of-life factors should help inform a treatment decision between the two therapies.

The findings comparing the effectiveness of definitive radiotherapy with primary surgery were published in JAMA Otolaryngology-Head & Neck Surgery.1

The investigators performed a comparative effectiveness analysis in patients with oropharyngeal squamous cell carcinoma (OPSCC), focusing on survival, side effects and costs. The study merged the HealthCore Integrated Research Database with state cancer registry data to identify 884 patients diagnosed with OPSCC from 2007 to 2014. The authors found no statistical differences between radiotherapy vs. surgery in overall survival, long-term gastrostomy dependence (stomach tube use), esophageal dilation or restriction, and bone toxicity effects. There was, however, an increase in acute gastrostomy use among radiotherapy patients who also received chemotherapy.

“While historical treatment outcomes for oropharyngeal cancer were quite poor, the combination of treatment innovations and more favorable tumor biology have resulted in three-year survival for over 75 percent of patients in this analysis,” said David Sher, M.D., associate professor of radiation oncology and of clinical sciences at UT Southwestern, and first author of this JAMA Otolaryngology study.

Sher believes that future research in this area should focus not just on oncologic results but also on patient quality of life and functional outcomes. “Both local therapy paradigms for HPV-associated oropharyngeal cancer are expected to change significantly over the next five years, so it is crucial to prospectively study the impact of novel treatment approaches on patient-centered outcomes.”

The study was funded by the Radiation Oncology Institute and co-authored by HealthCore, the outcomes research subsidiary for Anthem Inc.

It further showed that, for both treatments, costs were about $100,000 for payers and $5,000 for patients. Sher observed, “The absence of any significant cost differences further emphasizes how central patient-reported outcomes will be on the comparative value of the two therapies.”

Abiy Agiro, Ph.D., director of translational research at HealthCore concurred: “Our findings suggest that patient preference can be the main driver of local therapy selection as both surgery and radiation therapy were equally viable choices in terms of clinical outcomes with no cost difference.”

For more information: www.jamanetwork.com/journals/jamaotolaryngology

 

Reference

1. Sher D.J., Agiro A., Zhou S., et al. Commercial Claims–Based Comparison of Survival and Toxic Effects of Definitive Radiotherapy vs Primary Surgery in Patients With Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology-Head & Neck Surgery, Sept. 20, 2018. doi:10.1001/jamaoto.2018.1929

Related Content

CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...
Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones
News | Radiation Therapy | July 05, 2019
Aktina Medical announced that Elekta Instrument AB, based in Sweden, will offer and distribute the Aktina line of...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...